Wieland Heike A, Michaelis Martin, Kirschbaum Bernhard J, Rudolphi Karl A
Therapeutic Department Thrombosis & Osteoarthritis, Aventis Pharma Deutschland GmbH, a company of the Sanofi-Aventis group, Industrial Park Höchst, 65926 Frankfurt, Germany.
Nat Rev Drug Discov. 2005 Apr;4(4):331-44. doi: 10.1038/nrd1693.
Osteoarthritis is a painful and disabling disease that affects millions of patients. Its aetiology is largely unknown, but is most likely multi-factorial. Osteoarthritis poses a dilemma: it often begins attacking different joint tissues long before middle age, but cannot be diagnosed until it becomes symptomatic decades later, at which point structural alterations are already quite advanced. In this review, osteoarthritis is considered as a disease of the whole joint that may result from multiple pathophysiological mechanisms, one of which is the dysregulation of lipid homeostasis. No proven disease-modifying therapy exists for osteoarthritis and current treatment options for chronic osteoarthritic pain are insufficient, but new pharmacotherapeutic options are emerging.
骨关节炎是一种影响数百万患者的疼痛性致残疾病。其病因很大程度上尚不清楚,但很可能是多因素的。骨关节炎带来了一个难题:它往往在中年之前很久就开始侵袭不同的关节组织,但直到数十年后出现症状才能被诊断出来,此时结构改变已经相当严重。在本综述中,骨关节炎被视为一种可能由多种病理生理机制导致的全关节疾病,其中之一是脂质稳态失调。目前尚无经证实的可改变疾病进程的骨关节炎治疗方法,且慢性骨关节炎疼痛的现有治疗选择并不充分,但新的药物治疗选择正在出现。